Skip to content

NAtional TUnisian REgistry of Heart Failure

National Tunisian Registry of Heart Failure

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03262675
Acronym
NATURE-HF
Enrollment
2040
Registered
2017-08-25
Start date
2017-10-16
Completion date
2019-01-12
Last updated
2020-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Heart Failure, Acute Heart Failure, Chronic Heat Failure, Cardiovascular diseases, Heart diseases, Registry, Tunisia

Brief summary

NATURE-HF is an observational, multicentric and longitudinal study of heart failure performed with 100 tunisian cardiologists.

Detailed description

The NATURE-HF is a national clinical non-interventional registry of heart failure, carried out in Tunisia at cardiology departments in hospitals and in liberal cardiology consultations. 100 cardiologists participate in the enrollment of the eligible patients as investigators. A Committee of Experts validates the protocol methodology and supervises the data-management. A Steering Committee helps investigators to monitor their patient inclusions, performs audit trails and prepares the statistical analysis plan for the study. Collected data are managed by the DACIMA Clinical Suite®, the electronic data capture platform which complies with the FDA 21 CFR part 11 requirements (Food and Drug Administration 21 Code of Federal Regulations part 11), the HIPAA specifications (Health Insurance Portability and Accountability Act), and the ICH standards (International Conference on Harmonisation).

Interventions

None listed

Sponsors

Société Tunisienne de Cardiologie & de Chirurgie Cardio-Vasculaire
CollaboratorUNKNOWN
Dacima Consulting
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with chronic heart failure * Patient with acute heart failure (new onset or not) * The diagnosis of heart failure is at the discretion of the investigator * Informed and signed consent

Exclusion criteria

* Life expectancy \<12 months for extra cardiac disease * Isolated Right Heart Failure * Pregnant woman * Renal failure with creatinine clearance \< 15 ml / min * Hemodialysis patients * Cardiac surgery planned within 3 months * Congenital heart disease

Design outcomes

Primary

MeasureTime frameDescription
Cardiovascular deathTime-To-Event measure up to 12 months from baselineIncidence of cardiovascular death including sudden death, death from refractory heart failure and death from stroke

Secondary

MeasureTime frameDescription
Heart Failure ReadmissionAt 1, 3 and 12 months from patient enrollmentIncidence of heart failure readmissions
Global DeathTime-To-Event measure up to 12 months from baselineIncidence of death of all causes (cardiovascular death and non-cardiovascular death)

Countries

Tunisia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026